Hyperblot's First Beta Deployment Is Inside a Yale Neurology Lab

The Yale spinout's Hyperblot system, now in its first beta at the university, aims to replace a manual, decades-old protein analysis technique.

About ProteoWise

Published

For researchers studying the complex protein tangles of Alzheimer's disease, the Western blot is a familiar, if frustrating, companion. The decades-old technique is a manual, time-consuming, and sample-hungry process, often limiting how many protein targets a lab can analyze from a precious tissue sample. A Yale spinout, ProteoWise, is betting that a benchtop instrument called Hyperblot can replace that workflow, making multiplex protein analysis faster, cheaper, and accessible to more labs [ProteoWise].

In December 2024, the company quietly passed a key milestone, deploying its first beta system inside the very department where it was born: the Yale School of Medicine's Neurology Department [PRWeb, December 2024]. The placement is a logical first step for a tool built by neuroscientists, for neuroscientists, but its ambition is far broader. ProteoWise is aiming to simplify a foundational technique across academic and biopharmaceutical research.

The bet on an immortalized membrane

The company's core technological bet rests on what it calls an "immortalized membrane." In a standard Western blot, proteins are transferred to a membrane that is then probed with antibodies; the membrane can typically be used only once. ProteoWise's proprietary membrane is designed to capture and covalently bind proteins, allowing the same sample to be probed for multiple targets sequentially without degradation [ProteoWise].

This is packaged into the Hyperblot system, an integrated platform combining an automated instrument, single-use cartridges, reagents, and analysis software. The promised workflow is simple: a researcher inserts a sample, selects the protein analytes to interrogate, and presses start. The system is intended to output a quantified, multiplex data set, compressing what was a multi-day, manual process into a single automated experiment [ProteoWise].

The initial target is clear. The platform is positioned as a direct successor to the conventional Western blot, promising higher information content and throughput at a lower cost while using less sample volume [ProteoWise]. For translational labs moving from animal models to human tissues, where sample is extremely limited, that could be a decisive advantage.

A team steeped in translational neuroscience

ProteoWise's founding team reads like a page from a Yale neuroscience department directory, which is precisely the point. The company is a classic academic spinout, with deep roots in the problem it is trying to solve.

  • Erik Gunther, Ph.D., CEO. Gunther left a research faculty position at Yale School of Medicine to launch the company and co-developed the foundational technology [ProteoWise].
  • Mikhail Kostylev, Ph.D., Co-Founder. Kostylev advanced from graduate student to research faculty at Yale, where he developed the core technological advances for the platform [ProteoWise].
  • Stephen M. Strittmatter, M.D., Ph.D., Co-Founder. A professor and chair of Neuroscience at Yale, Strittmatter also directs the university's Alzheimer's Disease Research Center and has a track record of founding biotech companies based on lab discoveries [ProteoWise, Wikipedia].

This academic and clinical pedigree has helped attract investors focused on life sciences tools, including Connecticut Innovations, Cultivation Capital, and the National Institute on Aging [CB Insights, Perplexity Sonar Pro Brief]. The company has raised a reported $15.27 million across several rounds, with the most recent, a $2.31 million Series C, closing in December 2024 alongside the first beta deployment [CB Insights, Perplexity Sonar Pro Brief].

Round Reported Amount Reported Date
Early Round $6.3 million March 2020
Early Round $2.7 million April 2021
Series C $2.31 million December 2024
Table: Reported funding rounds for ProteoWise. Total disclosed funding is approximately $15.27 million [CB Insights, Perplexity Sonar Pro Brief].

Navigating a crowded tools landscape

The primary risk for ProteoWise is one of displacement and proof. The life sciences tools market is crowded with established giants and nimble startups, all vying for budget and bench space. The Western blot, for all its flaws, is a deeply ingrained, standardized technique. Convincing labs to alter a core protocol requires not just a compelling price-performance story, but robust data demonstrating reproducibility and accuracy that matches or exceeds the gold standard.

Furthermore, while the initial beta at Yale is a strong validation of concept, it is not yet a commercial sale. The company's next steps will be critical: moving from a friendly, academic beta site to paid deployments in biopharma and other academic institutions. The commercial ramp, sales cycle, and ongoing reagent revenue model for a hardware-plus-consumables business all remain to be proven at scale.

The company is also entering a market where other technological approaches to protein analysis, including mass spectrometry-based proteomics and other multiplex immunoassays, continue to advance. Hyperblot's niche is defined by its simplicity and direct replacement of an existing workflow, but it must continuously demonstrate that its multiplex capability and data quality keep pace with these broader field advancements.

For now, the focus is on the disease states where its founders have deep expertise: neurodegenerative conditions like Alzheimer's. In these fields, researchers are often working with minute, irreplaceable samples of human brain tissue. The current standard of care for protein analysis in this context is a painstaking patchwork of individual Western blots, ELISAs, and immunohistochemistry, processes that can consume weeks of a lab technician's time and milligrams of precious sample. ProteoWise's bet is that by collapsing that workflow into a single, automated run on the Hyperblot, it can accelerate the pace of discovery for the patients waiting for it.

Sources

  1. [ProteoWise] Our Technology | The Hyperblot Instrument | https://proteowise.com/our-technology/
  2. [PRWeb, December 2024] ProteoWise Deploys First Hyperblot™ System, Bringing the Power of Proteomics to Every Lab Bench | https://www.prweb.com/releases/proteowise-deploys-first-hyperblottm-system-bringing-the-power-of-proteomics-to-every-lab-bench-302332274.html
  3. [ProteoWise] Our Team | Our Seasoned Scientists at ProteoWise | https://proteowise.com/our-team/
  4. [Wikipedia] Stephen M. Strittmatter - Wikipedia | https://en.wikipedia.org/wiki/Stephen_M._Strittmatter
  5. [CB Insights] ProteoWise - Products, Competitors, Financials, Employees, Headquarters Locations | https://www.cbinsights.com/company/proteowise

Read on Startuply.vc